PZU Reports PLN 3 Billion Half-Year Net Profit
PZU Group reported a net profit of PLN 3.0 billion attributable to equity holders for the first half of 2026. PZU’s insurance revenue…
Novartis to Showcase Cardiovascular Data at ESC Congress
Novartis plans to present 10 abstracts on its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress. Late-breaking Phase 4 VICTORION-CHALLENGE…
dsm-firmenich Board Proposes Richard Ridinger as New Chairman
dsm-firmenich’s Board of Directors proposed Richard Ridinger as its next Chairman. The company said current Chairman Thomas Leysen will retire after his successor…
UPDATE: FDA Grants Priority Review to Breast Cancer Drug Datroway
• The drug, Datroway, is for patients with metastatic triple-negative breast cancer not eligible for immunotherapy. • A pivotal trial showed the drug…
UCB Epilepsy Drug Fenfluramine Shows Positive Phase 3 Results
UCB Reports Positive Phase 3 Results for Epilepsy Drug Fenfluramine in Rare CDD Disorder BRUSSELS – Global biopharmaceutical company UCB announced Thursday that…
Update: UCB’s Bepranemab Shows Promise In Alzheimer’s
UCB's Phase 2a study of bepranemab, an anti-tau antibody for Alzheimer's, will be presented at CTAD 2024. The study shows promise in delaying…
CHMP Recommends Wainzua For EU Approval For Hereditary Amyloidosis
AstraZeneca's Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
Update: Merck’s Clesrovimab Reduced RSV Disease, Hospitalization In Infants
Merck & Co., Inc. released news about their Clesrovimab (MK-1654) monoclonal antibody reducing RSV disease and hospitalizations in infants.
AstraZeneca Set to Showcase New Cancer Research at ASCO 2024
Plenary Presentations Highlight Tagrisso and Imfinzi’s Potential in Early Lung Cancer London, UK – This Tuesday, AstraZeneca confirmed that it is set to…
Truqap Plus Faslodex Recommended for EU Approval in Advanced Breast Cancer Treatment
AstraZeneca’s Combination Therapy Shows Significant Efficacy in Phase III Trial Cambridge, UK- On Monday, AstraZeneca’s combination of Truqap (capivasertib) with Faslodex (fulvestrant) received…